Peptide Initiative

Peptides · Peptide comparison

Pemvidutide vs Survodutide

Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.

Dual GLP-1/glucagon receptor agonist for obesity and metabolic liver disease

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangePemvidutide1.8–1.8 mgSurvodutide3.6–3.6 mg
FrequencyPemvidutideOnce dailySurvodutideOnce daily
AdministrationPemvidutideSubcutaneous injectionSurvodutidesubcutaneous injection
Cycle lengthPemvidutideOngoing/indefiniteSurvodutideOngoing/indefinite
Onset speedPemvidutideModerate (1-2 weeks)SurvodutideModerate (1-2 weeks)
Evidence levelPemvidutideModerate human trials (Phase 1-2)SurvodutideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Weight Loss

Pemvidutide92%
SurvodutideNo recorded rating

Liver Health

Pemvidutide95%
SurvodutideNo recorded rating

Metabolic Health

Pemvidutide88%
Survodutide9%

Weight Management

PemvidutideNo recorded rating
Survodutide9%

Blood Sugar Control

PemvidutideNo recorded rating
Survodutide8%

Technical data

Compound specifications

Pemvidutide

Molecular formula
C182H275N39O54
Molecular weight
3873.35 Da
Half-life
Approximately 110 hours (4.6 days)
Bioavailability
Subcutaneous bioavailability consistent with glycolipid-conjugated peptide therapeutics
CAS number
2538014-94-5

Survodutide

Molecular formula
C192H289N47O61
Molecular weight
4,231.6 Da
Half-life
~7 days (enabling once-weekly dosing)
Bioavailability
Optimized for subcutaneous administration with C18 acylation
CAS number
2805997-46-8

Protocols

Dosing compared

Pemvidutide

Subcutaneous

  • 48 weeks1.2 mgOnce weekly · 48 weeksLowest dose studied; given at full strength from week 1 with no titration. Produced ~10% weight loss at 48 weeks in the MOMENTUM Phase 2 obesity trial [6] and is the lower MASH dose in the IMPACT Phase 2b trial [7].
  • 48 weeks1.8 mgOnce weekly · 48 weeksMid dose, started at full strength with no titration; ~11% weight loss at 48 weeks (MOMENTUM) [6] and the higher MASH dose in IMPACT [7].
  • 48 weeks2.4 mgOnce weekly · 48 weeksHighest dose; reached via a 4-week titration in MOMENTUM, where it produced 15.6% weight loss at 48 weeks [6].

Survodutide

Subcutaneous

  • Initiation, part of a 20-week up-titration0.6 mgOnce weekly · Initiation, part of a 20-week up-titrationPhase 2 starting dose; gradual escalation reduces GI side effects [1].
  • 26-week maintenance after escalation3.6 mgOnce weekly · 26-week maintenance after escalationMaintenance dose in the phase 2 dose-finding trial; ~12.5% mean weight loss [1].
  • 26-week maintenance after escalation4.8 mgOnce weekly · 26-week maintenance after escalationHighest dose studied; up to ~14.9% mean weight loss over 46 weeks [1].

Applications

Best suited for

Pemvidutide

Adults seeking substantial weight loss without complex dose titration
Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].
Patients with metabolic syndrome who need comprehensive risk factor improvement
Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those interested in investigational dual agonist therapies with strong early data
Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][3].

Survodutide

Significant body weight reduction in obesity
Survodutide is particularly well-suited for individuals focused on significant body weight reduction in obesity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
MASH/NASH resolution and liver fibrosis improvement
Survodutide is particularly well-suited for individuals focused on mash/nash resolution and liver fibrosis improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Type 2 diabetes management with concurrent weight loss goals
Survodutide is particularly well-suited for individuals focused on type 2 diabetes management with concurrent weight loss goals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Enhanced metabolic outcomes through dual receptor engagement
Survodutide is particularly well-suited for individuals focused on enhanced metabolic outcomes through dual receptor engagement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Pemvidutide

Common

  • Nausea
  • Diarrhea
  • Headache

Uncommon

  • Vomiting
  • Decreased Appetite

Serious

  • Acute Pancreatitis
  • Severe Gastrointestinal Disturbance

Survodutide

Common

  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased Appetite

Uncommon

  • Constipation and Abdominal Pain

Serious

  • Acute Pancreatitis

Research status

Safety & evidence

Pemvidutide

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Pemvidutide (ALT-801, developed by Altimmune; a GLP-1/glucagon dual agonist) [3][5] completed Phase IIb obesity trials with favorable cardiovascular safety profile. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring. No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.

Contraindications

  • Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
  • Known hypersensitivity to pemvidutide or formulation components
  • History of acute pancreatitis
  • Severe hepatic decompensation (Child-Pugh C cirrhosis)

Survodutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
Research compound
Safety overview
Survodutide data comes from Phase 2 obesity and MASH trials with dose-dependent gastrointestinal side effects (gastrointestinal events in 75% on survodutide vs 42% on placebo in the obesity trial [1]; nausea 66%, diarrhea 49% and vomiting 41% in the MASH trial [6]) that mirror GLP-1 receptor agonist class effects but occur with greater frequency due to additional glucagon receptor activation increasing energy expenditure. Pancreatitis risk exists as with all GLP-1 agonists—baseline lipase evaluation and patient education on warning signs (persistent upper abdominal pain) are essential. Medullary thyroid carcinoma risk, though theoretical based on GLP-1 class, contraindicates use in MEN 2 or personal thyroid cancer history.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (GLP-1 class warning)
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known hypersensitivity to survodutide or excipients
  • History of pancreatitis (caution advised with GLP-1 receptor agonists)

Decision guide

Which is right for you?

Pemvidutide

Choose Pemvidutide if…

  • Adults seeking substantial weight loss without complex dose titration
  • Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
  • Patients with metabolic syndrome who need comprehensive risk factor improvement
  • Those interested in investigational dual agonist therapies with strong early data

Survodutide

Choose Survodutide if…

  • Significant body weight reduction in obesity
  • MASH/NASH resolution and liver fibrosis improvement
  • Type 2 diabetes management with concurrent weight loss goals
  • Enhanced metabolic outcomes through dual receptor engagement